Karen Moeremans

Summary

Affiliation: IMS Health

Publications

  1. ncbi request reprint Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea
    K Moeremans
    HEDM, Health Economics and Disease Management, Brussels, Belgium
    Int J Hematol 82:251-8. 2005
  2. ncbi request reprint Critical appraisal of scientific posters comparing anemia treatments for cancer patients: applying ISPOR Task Force guidelines on methodological quality of retrospective studies
    Nadia Demarteau
    IMS Health, Brussels, Belgium
    Crit Rev Oncol Hematol 63:91-9. 2007
  3. doi request reprint Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK
    Karen Moeremans
    IMS Health, Health Economics Outcomes Research, Brussels, Belgium
    Pharmacoeconomics 28:147-67. 2010
  4. doi request reprint Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK
    Karen Moeremans
    IMS Health, Health Economics Outcomes Research, Brussels, Belgium
    Pharmacoeconomics 28:107-28. 2010
  5. ncbi request reprint Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients
    Karen Moeremans
    HEDM IMSHealth, Crayerstraat 6, 1000 Brussels, Belgium
    Expert Opin Pharmacother 7:1931-43. 2006
  6. ncbi request reprint Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial
    K Moeremans
    Health Economics and Disease Management, Brussels, Belgium and Public Health Department, Ghent University, Ghent, Belgium
    Int J Gynecol Cancer 16:576-8. 2006
  7. ncbi request reprint An update: health economics of managing multiple myeloma
    K Moeremans
    HEDM, a unit of IMSHealth, Crayerstraat 6, 1000 Brussels, Belgium
    Eur J Cancer 42:1684-91. 2006
  8. ncbi request reprint Assessment of the economic value of the INTERCEPT blood system in Belgium
    K Moeremans
    HEDM, Health Economics and Disease Management, Brussels, Belgium
    Transfus Med 16:17-30. 2006
  9. ncbi request reprint Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer
    Karen Moeremans
    Health Economics and Disease Management, Meise, Belgium
    Value Health 7:472-81. 2004
  10. ncbi request reprint Long-term medical costs of postmenopausal breast cancer therapy
    V Cocquyt
    Department of Medical Oncology, University Hospital, Ghent, Belgium
    Ann Oncol 14:1057-63. 2003

Detail Information

Publications13

  1. ncbi request reprint Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea
    K Moeremans
    HEDM, Health Economics and Disease Management, Brussels, Belgium
    Int J Hematol 82:251-8. 2005
    ..Compared with current treatment with CAB, IVitra therapy was shown to be a cost-effective and cost-saving empirical treatment for PSFI in neutropenic cancer patients and BMT patients...
  2. ncbi request reprint Critical appraisal of scientific posters comparing anemia treatments for cancer patients: applying ISPOR Task Force guidelines on methodological quality of retrospective studies
    Nadia Demarteau
    IMS Health, Brussels, Belgium
    Crit Rev Oncol Hematol 63:91-9. 2007
    ..The ISPOR guidelines for the evaluation of retrospective analyses are a useful tool for assessing the quality of scientific posters...
  3. doi request reprint Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK
    Karen Moeremans
    IMS Health, Health Economics Outcomes Research, Brussels, Belgium
    Pharmacoeconomics 28:147-67. 2010
    ..These patients had a broader degree of previous PI use/failure (0 - ≥ 2) than the POWER patients...
  4. doi request reprint Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK
    Karen Moeremans
    IMS Health, Health Economics Outcomes Research, Brussels, Belgium
    Pharmacoeconomics 28:107-28. 2010
    ....
  5. ncbi request reprint Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients
    Karen Moeremans
    HEDM IMSHealth, Crayerstraat 6, 1000 Brussels, Belgium
    Expert Opin Pharmacother 7:1931-43. 2006
    ....
  6. ncbi request reprint Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial
    K Moeremans
    Health Economics and Disease Management, Brussels, Belgium and Public Health Department, Ghent University, Ghent, Belgium
    Int J Gynecol Cancer 16:576-8. 2006
    ..In conclusion, provided that a sufficient time horizon is taken and that long-term model predictions are confirmed from further follow-up from the ATAC study, anastrozole is a highly cost-effective adjuvant therapy compared to tamoxifen...
  7. ncbi request reprint An update: health economics of managing multiple myeloma
    K Moeremans
    HEDM, a unit of IMSHealth, Crayerstraat 6, 1000 Brussels, Belgium
    Eur J Cancer 42:1684-91. 2006
    ..There is also a clear need for peer reviewed economic evaluations of novel therapies such as thalidomide and Bortezomib in the treatment of multiple myeloma at different stages of the disease...
  8. ncbi request reprint Assessment of the economic value of the INTERCEPT blood system in Belgium
    K Moeremans
    HEDM, Health Economics and Disease Management, Brussels, Belgium
    Transfus Med 16:17-30. 2006
    ..3 million Euro per lifeyear), IBSP can be considered cost-effective, taking into account the potential risk of emerging pathogens...
  9. ncbi request reprint Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer
    Karen Moeremans
    Health Economics and Disease Management, Meise, Belgium
    Value Health 7:472-81. 2004
    ..To assess the cost-effectiveness of bicalutamide (Casodex) as adjuvant treatment in early prostate cancer (EPC)...
  10. ncbi request reprint Long-term medical costs of postmenopausal breast cancer therapy
    V Cocquyt
    Department of Medical Oncology, University Hospital, Ghent, Belgium
    Ann Oncol 14:1057-63. 2003
    ..From a health economic point of view, one is interested in the costs saved by disease prevention...
  11. ncbi request reprint European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment
    Lazzaro Repetto
    Istituto Nazionale di Riposo e Cura per Anziani, Unita Operativa di Oncologia, Via Cassia 1167, Rome 00189, Italy
    Cancer Treat Rev 32:S5-9. 2006
    ..Treatment of anaemia with ESAs is cost-effective and is associated with long-term gains in quality-adjusted life years...
  12. ncbi request reprint Estimating the cost-effectiveness of quality-improving interventions in oral anticoagulation management within general practice
    Neree Claes
    Department of General Practice, Catholic University Leuven, Leuven, Belgium
    Value Health 9:369-76. 2006
    ..The aim of the current study was to calculate the cost-effectiveness and influencing factors of the four quality-improving interventions compared with usual care...
  13. ncbi request reprint Modeling costs and cost-effectiveness of different CMV management strategies in liver transplant recipients as a support for current and future decision making
    Lieven Annemans
    Health Economics and Disease Management Meise, Belgium
    Value Health 5:347-58. 2002
    ..To develop a generic decision-analytic model to predict health and economic outcomes of different management options for cytomegalovirus (CMV) infection and disease in liver transplant patients...